Medline Inc. (MDLN)
NASDAQ: MDLN · Real-Time Price · USD
44.83
-0.01 (-0.02%)
Jan 27, 2026, 11:37 AM EST - Market open
Medline Stock Forecast
Stock Price Forecast
The 22 analysts that cover Medline stock have a consensus rating of "Buy" and an average price target of $47.41, which forecasts a 5.76% increase in the stock price over the next year. The lowest target is $40 and the highest is $52.
Price Target: $47.41 (+5.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Medline stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 |
|---|---|
| Strong Buy | 7 |
| Buy | 12 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $48 | Strong Buy | Initiates | $48 | +7.07% | Jan 12, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $50 | Buy | Initiates | $50 | +11.53% | Jan 12, 2026 |
| Stifel | Stifel | Strong Buy Initiates $46 | Strong Buy | Initiates | $46 | +2.61% | Jan 12, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $49 | Strong Buy | Initiates | $49 | +9.30% | Jan 12, 2026 |
| Deutsche Bank | Deutsche Bank | Hold Initiates $40 | Hold | Initiates | $40 | -10.77% | Jan 12, 2026 |
Financial Forecast
Revenue This Year
n/a
from 25.51B
Revenue Next Year
n/a
EPS This Year
1.21
from 0.07
Increased by 1,666.68%
EPS Next Year
1.50
from 1.21
Increased by 23.18%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.